These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10419904)

  • 41. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
    Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
    Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
    Weber-Nordt RM; Egen C; Wehinger J; Ludwig W; Gouilleux-Gruart V; Mertelsmann R; Finke J
    Blood; 1996 Aug; 88(3):809-16. PubMed ID: 8704235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway.
    Tauchi T; Yoshimura A; Ohyashiki K
    Exp Hematol; 2001 Mar; 29(3):356-61. PubMed ID: 11274764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
    Fernández de Mattos S; Essafi A; Soeiro I; Pietersen AM; Birkenkamp KU; Edwards CS; Martino A; Nelson BH; Francis JM; Jones MC; Brosens JJ; Coffer PJ; Lam EW
    Mol Cell Biol; 2004 Nov; 24(22):10058-71. PubMed ID: 15509806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines.
    Baśkiewicz-Masiuk M; Masiuk M; Machaliński B
    Cell Prolif; 2003 Oct; 36(5):265-78. PubMed ID: 14521520
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect on bcr-abl signaling pathway and the mechanisms of apoptosis induction by meisoindigo in K562 cells].
    Liu BC; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):815-8. PubMed ID: 19176035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
    Dai Y; Rahmani M; Pei XY; Dent P; Grant S
    Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors.
    Moucadel V; Constantinescu SN
    J Biol Chem; 2005 Apr; 280(14):13364-73. PubMed ID: 15677477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.
    Fernandez-Luna JL
    Apoptosis; 2000 Oct; 5(4):315-8. PubMed ID: 11227211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells.
    Poincloux R; Cougoule C; Daubon T; Maridonneau-Parini I; Le Cabec V
    J Cell Physiol; 2007 Oct; 213(1):212-20. PubMed ID: 17503465
    [TBL] [Abstract][Full Text] [Related]  

  • 54. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.
    Demoulin JB; Uyttenhove C; Lejeune D; Mui A; Groner B; Renauld JC
    Cancer Res; 2000 Jul; 60(14):3971-7. PubMed ID: 10919676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
    Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
    Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Signal transducer and activator of transcription proteins in leukemias.
    Benekli M; Baer MR; Baumann H; Wetzler M
    Blood; 2003 Apr; 101(8):2940-54. PubMed ID: 12480704
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dysregulated expression of COOH-terminally truncated Stat5 and loss of IL2-inducible Stat5-dependent gene expression in Sezary Syndrome.
    Mitchell TJ; Whittaker SJ; John S
    Cancer Res; 2003 Dec; 63(24):9048-54. PubMed ID: 14695224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
    Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
    Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.
    Hayakawa F; Towatari M; Iida H; Wakao H; Kiyoi H; Naoe T; Saito H
    Br J Haematol; 1998 Jun; 101(3):521-8. PubMed ID: 9633897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.